TIM-3作为急性髓系白血病的免疫与白血病干细胞生物标志物:诊断实验室与转化视角
本综述聚焦TIM-3(T细胞免疫球蛋白和黏蛋白结构域分子3)在急性髓系白血病(AML)中的诊断、预后及转化价值,整合多参数流式细胞术、转录与蛋白谱分析、可溶性免疫分析等技术,探讨其在复发风险分层、可测量残留病(MRD)优化、免疫图谱及伴随生物标志物开发中的潜在应用,并讨论影响临床适用性的实验室参数,指出TIM-3目前应视为有前景的辅助性AML生物标志物,不推荐在临床试验外单独用于常规临床决策。
要点
- TIM-3富集于CD34+CD38-白血病干细胞,正常造血干细胞表达有限,参与白血病微环境免疫检查点失调。
- TIM-3可通过多参数流式、HAVCR2转录/蛋白谱及可溶性TIM-3/Galectin-9免疫分析检测。
- TIM-3目前为有前景的辅助标志物,不推荐在临床试验外单独用于常规临床决策。
核心结论
- TIM-3应视为有前景的辅助性AML生物标志物,不推荐在临床试验外单独用于常规临床决策。
研究设计与样本
- 综述整合细胞、分子及可溶性分析平台(如多参数流式细胞术、HAVCR2转录与蛋白谱分析、TIM-3/Galectin-9可溶性免疫分析)的现有知识。
主要发现
- TIM-3富集于CD34+CD38- AML白血病干细胞,正常造血干细胞表达有限,并参与白血病微环境免疫检查点失调。
- TIM-3在复发风险分层、MRD优化、免疫图谱及伴随生物标志物开发方面具有潜在应用。
临床怎么用
- TIM-3目前可作为辅助性生物标志物用于AML相关检测与评估,但不应在临床试验外单独用于常规临床决策。
局限性
- 需统一检测工作流程、标准化结果报告、前瞻性验证阈值,并证明TIM-3在已知MRD和遗传风险模型之外的临床价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite improvements in ELN-based risk stratification, acute myeloid leukemia (AML) still faces three significant challenges: relapse, resistance to therapy, and measurable residual disease (MRD). T-cell immunoglobulin and mucin-domain-containing molecule 3 (TIM-3/HAVCR2) is a clinically relevant AML biomarker, as it is enriched in CD34+CD38- AML leukemia stem cells, with limited expression in normal hematopoietic stem cells, and is involved in immune-checkpoint disruption in the leukemic microenvironment. This review focuses on the diagnostic, prognostic, and translational value of TIM-3 in AML, particularly in relation to clinical chemistry and laboratory medicine. We integrated existing knowledge from various cellular, molecular, and soluble analytical platforms, such as multiparameter flow cytometry, to identify leukemia stem cells based on TIM-3 expression, transcript and protein profiling analysis of HAVCR2, or soluble immunoassay of TIM-3/Galectin-9. The potential applications of TIM-3 in relapse-risk stratification, MRD refinement, immune profiling, and companion biomarker development are further explored. Several important laboratory parameters that influence clinical applicability are also discussed in this review, such as specimen-matrix selection, antibody clone variation, gating strategies and cut-off variability pre-analytical procedures, and cross-platform validation. More harmonized assay workflows, standardized reporting of results, prospectively validated thresholds, and demonstration of the clinical value of TIM-3 beyond known MRD and genetic risk models are needed to enable the translation of TIM-3 into routine AML laboratory practices. Therefore, TIM-3 should currently be regarded as a promising adjunctive AML biomarker; however, it is not recommended for standalone routine clinical decision-making outside clinical trials.
引用
- Bhat AA, Fuloria S, Thapa R, et al. TIM-3 as an immune and leukemia stem-cell biomarker in acute myeloid leukemia: diagnostic laboratory and translational perspectives. Clin Chim Acta. 2026. PMID: 42309212. doi:10.1016/j.cca.2026.121187
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。